Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...

A CareSouth Carolina patient is among the first in the United States to receive a groundbreaking treatment aimed at slowing ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

A Hartsville hospital patient is among the first in the United States to receive a new treatment that helps slow the ...

discussed the potential of Eli Lilly's Alzheimer’s drug Kisunla (donanemab). At the time, the committee highlighted the lack of diversity in the enrollment population of the Phase III ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years.

For Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease, these new drugs mark an ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...